Foundry Therapeutics, Inc.

Jmedtech Coating Technologies Pte Ltd

Jmedtech (xiamen) Coating Technology Co. Ltd

Vascuros Medical Pte Ltd.

Vascuros Medical (shanghai) Co., Ltd.

Jingnan Luo

Honglei Wang

Hanson S Gifford, Iii

Karun D Naga

Koon Kiat Teu

Daniel Boon Lim Seet

Jackie Joe Hancock

Patrick H Ruane

Stephen W Boyd

Michael Steven Feldstein

Stephen A Boyd

Wei Li Lee

Michael Feldstein

John H Morriss

Mark E Deem

Martin L Mayse

Nassireddin Mokarram-Dorri

Qian Yi Michele Lee

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Implantable polymer depots for the controlled release of therapeutic agents

The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Implantable depots for the controlled release of therapeutic agents

There is provided a controlled-release antibiotic socket for securely holding an implantable medical device that is made from: at least one film having at least one polymer layer, where the at least one film is formed into the socket; at least one antibiotic agent; and at least one opening in the socket, where the at least one polymer layer comprises a biodegradable elastomeric polymeric material; and the at least one antibiotic agent is dispersed within at least one of the at least one polymer layers and/or, when the film comprises at least two polymer layers, the at least one antibiotic agent is disposed as a separate layer between two polymer layers. Also disclosed is the film used to make the socket and uses of both the socket and film.

Multi-layered polymer film for sustained release of agents

Disclosed herein is a drug-coated medical device in the form of a balloon having an inner surface and an outer hydrophobic surface, an adhesion balance layer directly on the outer hydrophobic surface of the balloon, comprising a hydrophilic polymer and/or a hydrophilic compound where the hydrophilic compound has a molecular weight of less than 1,000 Daltons, and a therapeutic layer directly on the adhesion balance layer comprising a therapeutic agent and a pharmaceutically acceptable carrier, wherein the therapeutic agent is a hydrophobic therapeutic agent with one or more hydrogen-bonding groups and is provided as discrete drug particles in the therapeutic layer, the drug particles have at least one dimension that is less than 25 μm and are uniformly distributed on the surface of the balloon, and the pharmaceutically acceptable carrier is hydrophilic and has a molecular weight of less than 1,000 Daltons. A process to make the drug-coated medical device and uses thereof are also disclosed.

Drug-coated medical devices

Described herein are coatings and formulations thereof for coating a substrate for use in producing a lubricious coating on a substrate surface that is to be inserted into the body lumen of a subject. Said coatings all contain an adhesion promoting coating formulation for applying to a substrate material that is formed from a polymeric adhesion promoter, a monomeric or polymeric crosslinking agent and a photoinitiator, where the polymeric adhesion promoter is a block copolymer comprising hydrophobic hydrophilic polymer blocks and/or a hydrophilic polymer comprising hydrophilic functional groups, where from 10% to 100% of the hydrophilic functional groups are capped with a hydrophobic functional group and the formulations thereof further contain a solvent to enable the coating to be applied to a substrate surface.

Coating compositions comprising adhesion promoting base layer

Growing community of inventors

Singapore, Singapore

Jingnan Luo